Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study.
about
Epigenetic approaches in the treatment of myelodysplastic syndromes: clinical utility of azacitidineSafety and efficacy of azacitidine in the treatment of elderly patients with myelodysplastic syndromeMyelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and managementNew ways to use DNA methyltransferase inhibitors for the treatment of myelodysplastic syndromeThe Value of Patient Reported Outcomes and Other Patient-Generated Health Data in Clinical Hematology.NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes.Epigenetic therapies for chemoresensitization of epithelial ovarian cancer.Cost-effectiveness analysis of azacitidine in the treatment of high-risk myelodysplastic syndromes in Spain.Demethylating Agents in the Treatment of CancerDNA hypomethylation in cancer cells.Treatment of myelodysplastic syndrome with 2 schedules and doses of oral topotecan: a randomized phase 2 trial by the Cancer and Leukemia Group B (CALGB 19803).Azacitidine for the treatment of patients with acute myeloid leukemia with 20%-30% blasts and multilineage dysplasia.Targeting DNA methylation for epigenetic therapy.Azacitidine: a review of its use in the management of myelodysplastic syndromes/acute myeloid leukaemia.Leukaemogenesis: more than mutant genesEpigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia.Clinical development of demethylating agents in hematologyThe role of azacitidine in the management of myelodysplastic syndromes (MDS).New treatments for myelodysplastic syndromesGemifloxacin for the treatment of respiratory tract infections: in vitro susceptibility, pharmacokinetics and pharmacodynamics, clinical efficacy, and safety.Hypomethylating agents and other novel strategies in myelodysplastic syndromes.DNA demethylating antineoplastic strategies: a comparative point of viewPattern of hypomethylating agents use among elderly patients with myelodysplastic syndromes.Opportunities for Trisenox (arsenic trioxide) in the treatment of myelodysplastic syndromes.Myelodysplastic syndromes: challenges to improving patient and caregiver satisfactionDevelopment of an oral form of azacytidine: 2'3'5'triacetyl-5-azacytidine.Novel therapies for patients with chronic myeloid leukemia.Emerging treatments in acute myeloid leukaemia.Therapy-related leukemia and myelodysplasia: evolving concepts of pathogenesis and treatment.Immunotoxin resistance via reversible methylation of the DPH4 promoter is a unique survival strategy.The role of methyltransferase inhibitors in the management of the myelodysplastic syndromes.The challenge of individualised risk assessment and therapy planning in elderly high-risk myelodysplastic syndromes (MDS) patients.Five-aza-2'-deoxycytidine-induced hypomethylation of cholesterol 25-hydroxylase gene is responsible for cell death of myelodysplasia/leukemia cells.Histone deacetylase inhibitors: a review of their clinical status as antineoplastic agents.The impact of iron overload and its treatment on quality of life: results from a literature review.Altered expression of topoisomerase IIalpha contributes to cross-resistant to etoposide K562/MX2 cell line by aberrant methylation.Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides.Rapid deterioration in quality of life during interleukin-2- and alpha-interferon-based home therapy of renal cell carcinoma is associated with a good outcomeAzacitidine in the management of patients with myelodysplastic syndromes.Managing myelodysplastic syndromes in very old patients: a teaching case report.
P2860
Q24608659-68CCFF55-D19D-4D6C-A4C1-6B47711A7B9BQ24632949-D81E7EA3-8B9B-4D3A-BA7F-D742968C22DCQ26796240-32F12184-A3B2-4623-ABCB-9ABA13129860Q26829132-90209FB5-D0B6-40EC-BE69-73E897D3EB11Q30964688-5643B62E-1275-4131-9883-9E716F9DB7E8Q33393647-85B1E3FE-D7CC-4F19-BBE8-0187D98829E2Q33621141-4F1A884A-040A-4833-8E10-0920B47E1710Q33644019-3972493D-F9D1-4CD8-9B08-74D90C80B725Q33678040-395E8A38-456C-413D-802F-23F582CFFABEQ33862334-06B9E621-99D1-41DF-A3EC-D14BD1B4973FQ33920750-0DF330F8-10C4-4A02-AD83-393BA5448DA3Q34172912-5D1FE7B6-7B3A-4A80-A025-330538ECFC12Q34258037-F01DC276-A7CA-4C68-9E23-511E14A946A1Q34273735-DBAB34BE-BF9D-4395-ACF2-A8CE5D215E0DQ34275371-CA469761-5A59-4E17-89E8-E6C94CAEEABEQ34350209-54D63291-F94F-41AC-9970-503DAF208D23Q34395179-5680162C-D002-4697-89E5-5E2C64FDB3B1Q34418429-B325E697-5A4C-4252-8BFC-003C070C4480Q34549290-5FE71DF6-FD24-46F6-86CB-534CFD3851B8Q34557714-9C272A62-9413-4CB5-B4B1-8F2484120BB6Q34667051-E1766689-044F-4494-8A43-D75FCC35F2F6Q34972245-29E51434-A802-40E7-896A-C9CC9CF03571Q35043089-CCF67C20-A1E7-4F2F-A09E-1BF7AD9D2CB0Q35186892-36F1D3B8-4D2C-4A44-8D61-EEB90497FF59Q35234485-95650AB3-ADF4-468F-8968-437527166E8AQ35687461-C7C67E10-6117-47B1-AD27-493A082F5CD9Q35728742-A088A756-5212-4A9B-9931-5EAB8280E6DCQ35779278-F78FC2E7-4C12-4723-9B63-4EB064E54473Q35809447-2A243F3F-E668-45CD-97D9-E054ACD92FB6Q35935802-1C22F980-8469-4399-A6C0-BDDD68FA1C4EQ35996501-F9E91DA4-764C-4A2C-A5D7-8A3B4C51B6CFQ36138278-6F2E0CB7-68AF-4AB6-860C-993C587F241BQ36290974-43DAD29F-57BD-44C0-8D0C-D00C631E74BCQ36321399-3430517F-5A5B-4AFC-8555-5B57DBF02358Q36606351-A4A3A0C3-5A8A-49D2-AF1C-82EC84FAC0BAQ36616756-8BADB227-1C56-4728-A734-3C66E482A369Q36642726-E01F5CC9-9601-4F17-A1D6-B267950F1380Q36670778-A04D1F9A-F774-439C-A44F-48CFA6306734Q36768610-9EA7D44F-3446-4092-9F16-026E2C7D0A2BQ36772626-5AC0965A-9B3F-4099-824E-101CFF97387A
P2860
Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh
2002年學術文章
@zh-hant
name
Impact of azacytidine on the q ...... er and Leukemia Group B study.
@en
Impact of azacytidine on the q ...... er and Leukemia Group B study.
@nl
type
label
Impact of azacytidine on the q ...... er and Leukemia Group B study.
@en
Impact of azacytidine on the q ...... er and Leukemia Group B study.
@nl
prefLabel
Impact of azacytidine on the q ...... er and Leukemia Group B study.
@en
Impact of azacytidine on the q ...... er and Leukemia Group B study.
@nl
P2093
P921
P356
P1476
Impact of azacytidine on the q ...... er and Leukemia Group B study.
@en
P2093
Alice B Kornblith
Bayard L Powell
Carlos DeCastro
Charles A Schiffer
Erin P Demakos
James E Herndon
James F Holland
John Ellerton
Lewis R Silverman
Rosalie Odchimar-Reissig
P304
P356
10.1200/JCO.2002.04.044
P407
P577
2002-05-01T00:00:00Z